News | December 12, 2013

Supersaturated Oxygen Therapy IDE Study Results in Smaller Infarct Size for Next-Generation System

TherOx Study Results Presented at TCT 2013

December 12, 2013 – TherOx Inc. released results from the company's multicenter investigational device exemption (IDE) pilot study that showed a 9.6 percent smaller infarct size at 30 days in high-risk patients treated with its next-generation system for Supersaturated Oxygen (SSO2) Therapy. This new therapy is intended to provide interventional cardiologists with the first treatment option beyond percutaneous coronary intervention (PCI) to salvage heart muscle in heart attack patients. The study results were presented at the 25th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation.

The next-generation SSOsystem shows great potential in improving upon the earlier successful results of a first-generation system. Patients treated with the second-generation SSO2Therapy system had a 9.6 percent median infarct size measured at 30 days. In a previous prospective, multi-center, randomized IDE trial, AMIHOT II, patients treated with the first-generation SSO2system had a 20 percent infarct size, and control group patients treated with PCI alone had a 26.5 percent median infarct size. The pilot IDE study enrolled 20 patients at three prominent cardiac centers in the United States.

“In the successful AMIHOT II study performed with the prior system, SSO2 Therapy was proven to reduce median infarct size by 26 percent, which is statistically significant. The new SSO2 system shows promise in producing even better results,” said Shukri David, MD, FACC, section chief of the division of cardiology at Providence Hospital near Detroit and the investigator for this study who presented the results at TCT.

The second-generation SSO2 Therapy system was designed to improve therapeutic effectiveness by perfusing the entire left coronary system so that no ischemic area goes untreated.  It also offers the additional benefit of shortening the treatment time to 60 minutes from 90 minutes. The original system only perfused the target artery treated with angioplasty and stenting.

According to the American Heart Association, every year approximately 1 million people in the United States have heart attacks. Although PCI is the standard of care in treating AMI, for many patients it doesn’t do enough to reduce infarct size and achieve maximum clinical benefit. SSO2 Therapy, adjunctive to PCI, is a solution of highly oxygenated saline mixed with the patient’s blood delivered through a catheter to the targeted ischemic area of the heart. SSO2 Therapy is intended to salvage the jeopardized myocardium and thus reduce infarct size, which correlates with improved cardiac function and mortality in heart attack patients. 

In the United States, SSO2 Therapy is delivered by an investigational device. It is limited by United States law to investigational use.  It is not for sale or distribution in the United States.

For more information:

Related Content

Corindus Announces First Patient Enrolled in PRECISION GRX Registry
News | Robotic Systems| September 18, 2017
September 18, 2017 — Corindus Vascular Robotics Inc.
Two-Year ILLUMENATE Trial Data Demonstrate Efficacy of Stellarex Drug-Coated Balloon
News | Drug-Eluting Balloons| September 18, 2017
Philips announced the two-year results from the ILLUMENATE European randomized clinical trial (EU RCT) demonstrating...
Sentinel Cerebral Protection System Significantly Reduces Stroke and Mortality in TAVR
News | Embolic Protection Devices| September 18, 2017
September 18, 2017 – Claret Medical announced publication of a new study in the...
Fysicon Receives FDA Approval for QMAPP Hemodynamic Monitoring System
Technology | Hemodynamic Monitoring Systems| September 18, 2017
Fysicon announced that it has been granted 510(k) clearance by the U.S. Food and Drug Administration (FDA) for its...
Marijuana Associated With Three-Fold Risk of Death From Hypertension
News | Hypertension| September 14, 2017
Marijuana use is associated with a three-fold risk of death from hypertension, according to research published recently...
Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Feature | Cath Lab| September 14, 2017
September 14, 2017 — Here are quick summaries for all the key late-breaking vascular and endovascular clinical trials
Mississippi Surgical and Vascular Center Uses Toshiba Ultimax-i FPD to Save Patients' Limbs
News | Angiography| September 14, 2017
The southern U.S. sees some of the highest numbers of chronic medical conditions, such as peripheral artery disease...
Sponsored Content | Videos | Structural Heart Occluders| September 13, 2017
Ziyad Hijazi, M.D., MPH, MSCAI, FACC, director of the cardiac program and chair of the Department of Pediatrics at Si
Philips Showcases Integrated Vascular Solutions at VIVA 2017
News | Peripheral Artery Disease (PAD)| September 13, 2017
Philips announced its presence at the Vascular Interventional Advances (VIVA 17) Annual Conference in Las Vegas from...
Medtronic Announces Japanese Regulatory Approval for In.Pact Admiral Drug-Coated Balloon
News | Drug-Eluting Balloons| September 13, 2017
Medtronic plc announced that the In.Pact Admiral Drug-Coated Balloon (DCB) received approval from the Japanese Ministry...
Overlay Init